Printer Friendly

Shin Nippon Biomedical Laboratories, Takeda Pharmaceutical Successfully Complete Joint Research on Cynomolgus Monkey.

Tokyo, Japan, June 26, 2006 - (JCN) - Shin Nippon Biomedical Laboratories (SNBL) announced on June 26 that it has completed a joint research project with Takeda Pharmaceutical.

Since 2002, the two companies have collaborated in the search and analysis of organ-specific virulence-associated genes of cynomolgus ("crab-eating") monkeys. The aim of this collaboration is to develop an effective tool for analyzing and estimating the toxicity of drug candidates.

Through the four-year collaboration, the partners have analyzed genes expressed in the six main organs of cynomolgus monkeys and established a database that covers the entire genome sequences of cynomolgus monkey.

Further, they have created a customized DNA microarray that mounts representative sequences from 15,000 genes. Subsequently, they have confirmed that the customized DNA microarray can be used to evaluate toxicity in primates. Further, they have developed a gene expression database for 27 organs used in toxicity analysis.

Details of the joint research were presented at the 46th Annual Meeting of the Society of Toxicology and will be presented at the 33rd Annual Meeting of the Japanese Society of Toxicology, to be held in Nagoya in July.

Going forward, SNBL plans to proceed with research and aims to develop an innovative tool for toxicity analysis of drug candidates.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Jun 27, 2006
Words:215
Previous Article:Pfizer Japan Surveys Smokers.
Next Article:Teijin Pharma, Sato Pharmaceutical Jointly Introduce Antipsoriatic Agent Bonalfa.


Related Articles
Evaluation in nonhuman primates of vaccines against Ebola virus. (Perspectives).
Shin Nippon Biomedical Laboratories, Biomarker Science to Collaborate in Preventive and Integrated Medicine.
Shin Nippon Biomedical Laboratories Subsidiaries, Tokai Pharmaceuticals to Collaborate in Nasal Drug Delivery Technology.
US District Court Dismisses Abbott Laboratories' Litigation Against Takeda Pharmaceutical.
Shin Nippon Biomedical Laboratories Obtains New Knowledge on Drug-metabolizing Enzyme Cytochrome P450.
Translational Research Develops Intranasal Formulation of Granisetron, Antiemetic Agent.
Takeda Pharmaceutical to Establish New Sales and Marketing Company in London.
Takeda Pharmaceutical, Galaxy Biotech to Sign Licensing Agreement for HuL2G7, Investigational Agent for Cancer Treatment.
Takeda Announces Start of Phase 3 Clinical Program in the U.S.of Fixed Dose Combination Product of Actos(R) + TAK-536for Treatment of Patients with...
London Symphony Orchestra and Takeda Pharmaceutical Company Launch the 7th Takeda Global Concert Series.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters